Investor Relations

Print   Email  
Stock price graph
     

Ocera is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's lead program, OCR-002, is an ammonia scavenger designed to treat hyperammonemia (elevated ammonia in the blood) and associated hepatic encephalopathy, a complication of patients with liver cirrhosis.

View all »   RSSRecent Releases

Sep 1, 2015
Ocera to Present at the Rodman & Renshaw 17th Annual Global Investment Conference

Aug 3, 2015
Ocera Therapeutics Reports Second Quarter 2015 Financial Results

View all »Events & Presentations

Sep 10, 2015 at 3:00 PM ET
Rodman & Renshaw 17th Annual Global Investment Conference

Oct 20, 2015
2015 BIO Investor Forum

Investors